# A Study of Irinotecan Liposome in Advanced Pancreatic Cancer

> **NCT04796948** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 41 (actual)

## Conditions studied

- Advanced Pancreatic Cancer

## Interventions

- **DRUG:** Irinotecan liposome；oxaliplatin；5-FU(Fluorouracil Injection)；LV(Calcium Folinate Injection)

## Key facts

- **NCT ID:** NCT04796948
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-08
- **Primary completion:** 2024-06-28
- **Final completion:** 2024-06-28
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04796948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04796948, "A Study of Irinotecan Liposome in Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04796948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*